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Abstract: Feline infectious peritonitis (FIP) is a coronavirus-induced disease of cats, in which the
immune system is known to play a crucial, but complex, role in the pathogenesis. This role is still
incompletely understood, with involvement of both host and viral factors. To evaluate differential
gene expression and pathway involvement in feline coronavirus (FCoV) infection and FIP, we applied
next-generation RNA-sequencing of the mesenteric lymph nodes from cats with naturally-acquired
FIP, as well as those with systemic FCoV infection without FIP, and those with neither. Viral infection
was associated with upregulation of viral defenses regardless of the disease state, but to a greater
degree in FIP. FIP was associated with higher pro-inflammatory pathway enrichment, whilst non-FIP
FCoV-positive cats showed lower enrichment of humoral immunity pathways, below that of uninfected
cats in the case of immunoglobulin production pathways. This host response is presumed to be
protective. In FIP, downregulation of T cell-related processes was observed, which did not occur in
non-FIP FCoV-positive cats. These results emphasize the importance of the host’s immune balance in
determining the outcome of the FCoV infection.
Keywords: RNA-seq; next-generation sequencing; cell mediated immunity; humoral immunity;
FCoV; FIP
1. Introduction
Feline infectious peritonitis (FIP) is a fatal immune-mediated disease of domestic and wild felids
caused by feline coronavirus (FCoV), a highly prevalent virus with a worldwide distribution which
infects domestic and wild felids. FCoV is an alphacoronavirus, similar to several respiratory and enteric
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pathogens in other species, such as canine coronavirus (CoV), porcine transmissible gastroenteritis
CoV, and the ‘common cold’ CoVs of humans. It differs at the genus level from the betacoronaviruses
that include the severe respiratory disease-causing CoVs of humans (SARS-CoV 1 and 2, MERS-CoV),
and the gammacoronaviruses of birds. As a member of the subfamily Orthocoronavirinae, it belongs to
a different subfamily than known nidoviruses of reptiles and mammals [1,2]. FCoV initially infects
enterocytes via the fecal-oral route and in most cases causes only a mild or subclinical enteric disease.
The first stage of gaining increased pathogenicity involves infecting monocytes, enabling systemic
spread [3]; this may occur in cats which remain healthy without progression to FIP [4]. In ~5% of
infected cats, a combination of, as yet only partially understood viral and host factors lead to the
development of FIP [5,6]. FIP is characterized by (pyo) granulomatous phlebitis, generally accompanied
by more extensive pyogranulomatous lesions and, in many cases, cavitary effusions [7–9].
Numerous studies have tried to pinpoint a key viral mutation leading to the disease of FIP.
However, this has so far proven inconclusive [10,11]. Certain amino acid switches in the spike protein
(which mediates host binding) were initially linked to pathogenicity but have since been shown to
indicate systemic spread [12–15]. The quest for a defining mutation is also made more difficult by
the large size of the virus (30 Mb), and its high mutation rate. The latter is a consequence of the low
fidelity of the viral RNA polymerase and high tendency for natural homologous recombination due to
random template switching during the complex viral replication [16–18]. Together, these factors mean
that sequencing of the virus coding RNA alone may be insufficient to identify pathogenicity markers.
Susceptibility to disease has been shown to be heritable to some extent, suggesting a genetic
component [19–21]. Additionally, experimental studies with known pathogenic forms of FCoV have
shown that some cats remain resistant to infection, confirming the importance of the host response in
disease susceptibility [22–24]. Therefore, the immune response of healthy infected cats is of particular
interest. Disentangling the virus and host effect in natural infections is complex; given the current
absence of clearly defined viral markers of pathogenicity, it cannot be definitively determined whether
healthy systemically FCoV-infected cats are those who are resistant, through suppressing a high
viral replication as well as limiting their own inflammatory response, or are instead infected with a
‘non-pathogenic’ form. However, as the pathogenic forms arise from mutations to the non-pathogenic
form, hosts which are able to suppress viral replication will, in any case, reduce their chances of
succumbing to the disease. It is known that systemically infected disease-free cats have lower viral
levels than those with FIP [12,25], but also that, experimentally at least, monocytes/macrophages are
less supportive of replication of ‘non-pathogenic’ strains [26,27].
The hallmark pathological processes of FIP, monocyte-mediated granulomatous phlebitis and
systemic endothelial activation, the changes in the lymphatic tissue (such as lymphocyte depletion)
together with clinical signs such as fever, all indicate an excessive and inappropriate immune
response [3,28,29]. Therefore, inflammatory cytokines have been a frequent focus of study, yet no
single organ has been shown to be convincingly responsible for the apparent cytokine storm [30–33].
Furthermore, there is evidence that non-primary immune organs such as the liver and heart may also
contribute to cytokine production, adding an amplification step [34]. Despite the disease being caused
by an excessive immune reaction, immunosuppressed cats are known to be predisposed to FIP [35],
suggesting that mounting a successful immune response is a precarious balancing act which we do
not yet sufficiently understand. Identifying genetic markers of susceptibility has also been a focus of
study; however, genes first found to be of interest in specific breeds subsequently lost significance in
more widespread population searches [20,36]. Counter-intuitively, inbreeding of resistant cats led to
increased rather than reduced susceptibility [37], supporting the theory that loss of heterozygosity
represents the so-called hybrid vigor risk factor.
Utilizing a rare biobank from cats with FIP, as well as FCoV-infected and uninfected cats without
FIP, we previously evaluated mesenteric lymph nodes (MLN) for expression of selected immune
mediators and found a possible intermediate stage of activation, represented by upregulation of some
mediators, in FCoV-infected cats without FIP [12]. Natural FCoV infection is via the fecal-oral route
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and the MLN guard the gateway between the external (i.e., intestinal) and internal environment, able to
detect and respond first to the inadvertent entry of pathogens [38]. Together with other hemolymphatic
organs, MLN have previously been assessed for levels of specific cytokines and for changes in leukocyte
populations in FIP [30,39–41]. In the current study, we have used next-generation RNA-sequencing of
the MLN to evaluate differential gene expression and pathway involvement in FCoV infection and FIP.
In the context of FIP, this technique has thus far only been applied in an in vitro study and to peritoneal
macrophages of experimentally-infected cats [42–44]. In both settings, apoptosis-related genes were
found to be highly upregulated, consistent with observations at a morphological level of lymphoid
depletion [39,41]. Peritoneal macrophages were not found to show convincing Th2 polarization
in FIP [42] despite the common understanding that cell-mediated immunity is protective and Th2
(humoral) immunity is detrimental [45]. Antibody-dependent enhancement is thought by many to be
a feature of the disease [6,46–48]. However, cross talk between individual cells and cell types is crucial
to determining the balance and response type of the immune system. Therefore, we aimed to evaluate
the immune response at an organ level in natural infections, which mirror the real-life clinical situation.
We hypothesized that cats with FIP would show a higher differential expression of humoral immunity
than those with FCoV infection only, as well as an overall higher activation level of pro-inflammatory
pathways. We found that, in contrast to cats with FIP (hitherto referred to as FIP cats for brevity),
FCoV-infected cats without FIP showed a lower enrichment of humoral immunity pathways (hitherto
referred to as non-FIP cats for brevity). Conversely, cats with FIP exhibited downregulation of T
cell-related processes, the loss of which can be predicted to impair the immune response. Enhancing
our understanding of the host response and genetic determinants of the disease outcome might not
only allow for future targeting of therapeutics but potentially also for targeted breeding programs.
2. Results
Reverse-transcriptase-quantitative PCR (RT-qPCR) results for FCoV in the MLN of these cases
have been previously published [12–14] and are included with the signalment in Supplementary Table
S1. These showed viral loads to be far higher in FIP cats than in FCoV-positive non-FIP cats, the former
having cycle threshold values ranging from 15.1 to 19.8 and the latter from 34.9 to 39.8 (indicating a
factor difference of over 104 at the closest values).
2.1. Read Quality and Summary of Transcriptional Profiling
The sequencing of the RNA libraries generated on average 25.3 Mio reads (7.1–58.1, SD = 15.1).
The mappability of these reads was high (89.7% on average) and remarkably consistent, with a narrow
range of 87.4 to 89.8%. Between 59 and 72% of the mapped reads were assigned to coding regions
and contributed to the estimation of the gene expression levels. Together with the summary of the
quantification and the pair-wise comparisons, this is shown in Supplementary Figure S1. Moreover,
the fraction of the ribosomal reads in the samples and their strandedness is shown in Supplementary
Figure S2.
Based on the expression profiles, a clear separation between FIP cats and non-FIP cats was
obtained by means of multidimensional scaling (MDS) (Figure 1). To a lesser extent, non-FIP cats
also clustered into FCoV-positive and FCoV-negative along the secondary axis. In order to ensure
that the effect of secondary variables was not acting as a confounder, we performed additional MDS
clustering with additional annotation and a PERMANOVA analysis. Neither secondary data structure
nor confounding effects from covariates were found (Supplementary Figure S3). The number of
dysregulated genes identified by differential expression (DE) analysis for the pairwise comparisons
revealed that differences within the non-FIP group (i.e., between those infected and those not infected
with FCoV) were comparatively limited, with approximately 5% the number of DE genes (146) as
when the FIP group was compared to either (or a combined) FIP group (G1, G1_Neg, G1_Pos, with
2845, 2565, and 2144 DE genes, respectively).
Pathogens 2020, 9, 524 4 of 19
−0.50
−0.25
0.00
0.25
0.50
0.75
−0.4 0.0 0.4
PC1 (86.41% )
PC
2 
(7.
24
% 
) Group
G1_Neg
G1_Pos
G2
Figure 1. Multidimensional scaling plot showing a main segregation of feline infectious peritonitis (FIP)
cats (G2) from both G1 (non-FIP) subgroups (feline coronavirus (FCoV) negative G1_Neg; FCoV positive
G1_Pos) along the leading dimension. Segregation within G1 is also observed, but to a lesser extent.
2.2. FIP Cats Versus Non-FIP Cats (G2 vs. G1)
Figure 2 shows the expression profiles of the significantly up and downregulated genes from the
MLN of FIP cats (G2) as compared to the non-FIP cats (G1). Two well-defined gene clusters are visible,
representing transcriptional signatures for FIP and the non-FIP groups.
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Figure 2. Heatmap of the expression levels of the genes which are differentially regulated between
mesenteric lymph nodes from cats with FIP (G2), and cats without FIP (G1_Pos and G1_Neg). The
expression levels are log-normalized and scaled row-wise.
In order to perform an ensemble functional analysis of the differences in the transcriptional
patterns between the groups, we selected from the pair-wise comparisons genes with a p-value below
0.05 and a log2ratio above (or below) 0.5. These sets of up or down regulated genes were used as
inputs for the GO databases.
Functional analysis of the genes significantly upregulated in FIP reveals 83 enriched gene ontology
(GO) terms associated to a biological process (BP) (Supplementary Table S2). They all refer either
directly to the immune system or to a related process (e.g., signaling pathways). The significant
processes represent responses to both viral (e.g., defense response to virus) and bacterial (e.g., defense
response to bacterium) infection as well as phagocytosis, apoptosis, and pro-inflammatory processes
such as IL-6 production, chemotaxis, and complement activation. Both innate and adaptive immune
processes are enriched, with multiple terms referring to B cell signaling, activation, and antibody
production. Figure 3 shows the ten most enriched GO BP terms of this analysis. Molecular function
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(MF) terms are similar to BP terms, whilst cellular component (CC) categories mainly relate to the
endoplasmic reticulum and Golgi apparatus, presumed secondary to viral packaging [49].
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Figure 3. Enrichment of gene ontology (GO) categories based on genes differentially regulated in
mesenteric lymph nodes of FIP cats (G2) as compared to the non-FIP cats (G1). The hypergeometric
test without replacement is used. “Count” is the number of genes belonging to the category and
also differentially expressed in the comparison while the x-axis is the ratio between “Count” and the
total number of genes in the category. “Fdr” is the Benjamini-Hochberg-adjusted p-value derived
from the hypergeometric test. (A) Downregulation driven enrichment in FIP; (B) upregulation driven
enrichment in FIP.
When individual genes are looked at, and ranked by fold-change between groups, the top 20
upregulated in FIP includes IRF7, IFIT2&3, and ISG15 (all IFN pathway genes) as well as C5, CCL8,
and CXCL10 (complement pathway component and chemokines, respectively).
A single BP GO term is higher in non-FIP cats: Peptidyl-tyrosine autophosphorylation; however,
the CC term GO:0042101 (T cell receptor complex) is also higher in these cats.
2.3. FIP Cats Versus Non-FIP Cats Without Detectable FCoV in the Mesenteric Lymph Nodes (G2 vs. G1_Neg)
Figure 4 shows the top BP GO terms enriched for genes significantly up and downregulated in the
MLN of FIP cats, respectively, as compared to FCoV-negative non-FIP cats without FIP (G1_Neg). The
former consists of 90 GO terms, overlapping heavily with the previous comparison, of MLN from cats
with FIP versus cats without FIP (see Supplementary Table S3). Almost all terms enriched in FIP relate
directly to the immune response, with some indirectly related, e.g., protein secretion and transport
required for processes such as cytokine production. Both innate and acquired immune responses are
represented including inflammatory cytokines and immunoglobulin production. Both anti-viral and
anti-bacterial pathways are enriched. The top DE genes higher in MLN from FIP cats again include
CCL8 and interferon-inducible/related genes. The main differences are in the terms downregulated
in MLN from FIP cats which are more numerous in this comparison; there are four terms including
immune specific ‘T cell receptor signaling pathway’ and ‘positive regulation of IL-4 production’.
2.4. FIP Cats Versus Non-FIP Cats with FCoV Positive Mesenteric Lymph Nodes (G2 vs. G1_Pos)
The functional analysis of differentially expressed genes between these groups reveals that the
significantly enriched GO terms are again almost exclusively driven by genes upregulated in the
MLN of FIP cats, with three exceptions (Figure 5). The most enriched terms associated to genes
upregulated in FIP are again highly similar to the previous pairwise comparisons and include viral
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defense responses and phagocytosis (see Supplementary Table S4). Individual genes higher in FIP are
similar to those listed above.
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Figure 4. Enrichment of gene ontology (GO) categories based on genes differentially regulated in
mesenteric lymph nodes from FIP cats (G2) as compared to FCoV-negative non-FIP cats (G1_Neg).
The hypergeometric test without replacement was used. “Count” is the number of genes belonging to the
category and also differentially expressed in the comparison while the x-axis is the ratio between “Count”
and the total number of genes in the category. “Fdr” is the Benjamini-Hochberg-adjusted p-value
derived from the hypergeometric test. (A) Downregulation driven enrichment in FIP; (B) upregulation
driven enrichment in FIP.
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Figure 5. Enrichment of gene ontology (GO) categories based on genes differentially regulated in
mesenteric lymph nodes from FIP cats (G2) as compared to FCoV-positive non-FIP cats (G1_Pos).
The hypergeometric test without replacement was used. “Count” is the number of genes belonging to the
category and also differentially expressed in the comparison while the x-axis is the ratio between “Count”
and the total number of genes in the category. “Fdr” is the Benjamini-Hochberg-adjusted p-value
derived from the hypergeometric test. (A) Downregulation driven enrichment in FIP; (B) upregulation
driven enrichment in FIP.
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2.5. Non-FIP Cats with and without Detectable FCoV in the MLN (G1_Pos vs. G1_Neg)
Comparing the MLN data from the subgroups of non-FIP cats (i.e., FCoV-positive G1_Pos vs.
FCoV-negative G1_Neg) resulted in far fewer DE genes and hence fewer significantly enriched GO
terms (15; see Figure 6 and Supplementary Table S5, all of which were enriched up in the FCoV
infection). Terms higher in FCoV positive cats (G1_Pos) relate to viral defense, leukocyte chemotaxis,
and cytokine/chemokine signaling and responses. Bacterial defense and phagocytosis are not observed
to be enriched. Many IFN related genes are higher in FCoV positive cats (G1_Pos).
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Figure 6. Enrichment of gene ontology (GO) categories based on genes differentially upregulated in
mesenteric lymph nodes from FCoV-positive non-FIP cats (G1_Pos) as compared to FCoV-negative
non-FIP cats (G1_Neg). The hypergeometric test without replacement was used. “Count” is the
number of genes belonging to the category and also differentially expressed in the comparison while
the x-axis is the ratio between “Count” and the total number of genes in the category. “Fdr” is the
Benjamini-Hochberg-adjusted p-value derived from the hypergeometric test.
2.6. Overlap Comparison of the Host Response to FCoV in FIP Cats and Non-FIP Cats (G2 vs. G1_Neg and
G1_Pos vs. G1_Neg)
Results of the two comparisons between FCoV-positive and FCoV-negative cats (G2 vs. G1_Neg
and G1_Pos vs. G1_Neg) were themselves compared to identify the extent of differences in the MLN
response when infection outcome (i.e., FIP or not) was considered. A Venn diagram (Figure 7) shows
that of all significant DE genes in the two comparisons, 2094 are significant only in the FIP comparison
(G2 vs. G1_Neg), 51 only in the comparison between FCoV-positive and FCoV-negative subgroups of
non-FIP cats (G1_Pos vs. G1_Neg), and 66 overlapped. Each of these sets of genes was further split by
direction of their dysregulation (e.g., genes DE in the MLN of FIP cats but not in FCoV-positive cats
non-FIP cats, and associated with a positive expression log2-ratio). This resulted in a low number (30)
of genes upregulated in FCoV-positive non-FIP cats, and no significant functional enrichment was
found. In contrast, there were over 1000 genes upregulated exclusively in the MLN from cats with FIP,
these showed myriad enrichment for inflammatory features (including Myd88 toll-like receptors (TLR)
signaling), and apoptosis. In looking at the individual genes upregulated in the MLN from cats with
FIP and not in FCoV-positive non-FIP cats, some of note include CXCL10, TLR2, TLR4, TLR8, IL-1β,
IL-6, and TNF. Genes involved in IFN pathways (e.g., ISG15 and 20, TRIM25, IFIT2, and IFIT3) are
found elevated in the overlap of both FCoV-positive groups (G2 and G1_Pos). FOXP3 is amongst the
955 genes lower in FIP than in FCoV-positive non-FIP cats and not significantly DE in the latter.
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Figure 7. Intersection of the set of differentially expressed genes in the comparisons between FIP
cats and non-FIP cats with and without detectable levels of FCoV. The header number represents the
number of genes found in the areas of the Venn diagram. The genes listed are the 10 most differentially
expressed in the comparisons. For the genes which are differentially expressed in both comparisons,
the ranking is based on a score calculated as follows (the lower the score, the higher the ranking): Score
= [p (comp1) + p (comp2)]/abs (log2Ratio (comp1) + log2Ration (comp2)).
2.7. Evaluation of GO Categories at the Gene Level
A subset of GO biological processes deemed of most interest was further analyzed in order to
compare ensemble gene expression within categories between groups (see Figure 8). Considering the
implication of cell mediated immune response mechanisms we chose to interrogate other T cell-related
pathways at the gene level, in addition to reporting the reduced role in FIP cats of the T cell receptor
signaling pathway, to see if a similar pattern could be identified.
In most cases the gene expression levels were higher in the MLN from cats with FIP (G2) than in
both non-FIP subgroups (G1_Pos, G1_Neg). GO:006910 (phagocytosis recognition) additionally showed
significantly higher levels in FCoV-negative than in FCoV-positive non-FIP cats; within GO:0032481
(positive regulation of type I interferon production) gene levels between the two non-FIP groups
were found to be slightly higher but not significantly so in FCoV-positive cats. The two T cell-related
categories (GO:0030217; T cell differentiation and GO:0002456; T cell mediated immunity) both had gene
levels in MLN from FIP cats significantly lower than in the non-FIP subgroups, which were themselves
not significantly different from each other. Genes of GO:0032755 (positive regulation of interleukin-6
production) were higher in MLN from FIP cats than in either non-FIP subgroup, which were again
similar between themselves. Immunoglobulin production category genes (GO:0002377), though higher
in the MLN from FIP cats, were lower in FCoV-positive than in FCoV-negative non-FIP cats.
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Figure 8. Boxplot of the mesenteric lymph node expression levels of the genes identified beyond
background noise and annotated to the following gene ontology (GO) terms: GO:006910-phagocytosis
recognition; GO:032481-positive regulation of type I interferon production; GO:030217-T cell
differentiation; GO:002456-T cell mediated immunity; GO:032755-positive regulation of interleukin-6
production; GO:002377-Immunoglobulin production. G1_neg–non-FIP FCoV negative; G2-FIP;
G1_pos–non-FIP FCoV positive. The value is the log-scaled expression from the individual genes.
p-values are calculated with a Wilcoxon signed rank test.
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3. Discussion
The results of the present study for the first time provide detailed information on how the immune
system responds to FCoV infection in natural cases, both in animals succumbing to FIP and those
showing no clinical or pathological signs attributable to FIP. In focusing on the MLN, we chose to
study an organ that is consistently involved in FCoV infection [50], as well as being an immune organ
with a vital role in both detecting and responding to the virus. Significant differences between cats
with and without FIP were observed. These were surprisingly consistent given the variation in the
disease stage, distribution of lesions, and clinical findings of the FIP cases as well as the varying clinical
conditions of the cats without FIP. This may reflect the fact that, despite clinically high variability, the
pathogenic and pathological processes are stereotypic in FIP. In studying the MLN, we appreciate that
different cell types and subsets contributed to the results, but the main cell types present will generally
be B cells, T cells, and macrophages (the latter having been shown to increase in number in FIP [39]).
Viral loads varied greatly between cats with FIP (up to a 100-fold) despite similar RNA-sequencing
based transcriptional profiles, showing that the number of infected cells is not likely to be crucial to the
organ’s response.
Thousands of genes were found to be dysregulated in the MLN of cats with FIP, pointing to
numerous immune and inflammatory pathways, most of which were predictable or consistent with
known features of the disease. Viral defense and negative regulation of viral replication were found
to be enriched in FCoV infection regardless of FIP status, but at significantly higher levels in cats
with FIP, demonstrating that the host attempts, albeit unsuccessfully in cats with FIP, to respond
appropriately. Similarly, processes related to the prototypic anti-viral cytokines, type I and II IFN
were also enriched in FCoV infection regardless of FIP status, whilst IFN pathway genes were heavily
overrepresented amongst the top DE genes found to be higher [51]. However, type I IFN genes
themselves were not upregulated. Pro-inflammatory cytokine activation was also a feature; processes
upregulating all three of the feline inflammatory triad of IL-1β, IL-6, and TNF-α [52] were enriched in
the MLN of cats with FIP in the present study (as were the mediators themselves when previously
investigated [12]), again consistent with clinical signs. These were upregulated to a lesser degree
in FCoV-positive cats without FIP, supporting a beneficial intermediate stage of activation. We also
found enhanced complement pathways which complements observations of increased circulating
complement in the disease state [53]. Phagocytosis was identified as an enriched process in the MLN
of cats with FIP but not in FCoV-positive cats without FIP, in which it was actually lower than in
FCoV-negative cats. This may be host- or virus-specific and in some way protective in FIP, linking
to the phenomenon of antibody-dependent enhancement observed in experimental FIP, seemingly
representing another detrimental feature of the immune response in this disease [54]. The relative lack
of observed anti-inflammatory regulatory processes in the MLN of cats with FIP may help explain the
exuberance of the response, despite previous studies not finding consistently excessive levels of the
inflammatory cytokines themselves [12,30,33,41].
We also identified that bacterial response pathways were upregulated in the MLN of cats with
FIP. There are two likely explanations for this observation. One is an overlap in function between
pattern recognition receptors (PRR) responsible for detecting pathogens, e.g., TLRs 2, 4, and 8 were all
upregulated in the MLN of cats with FIP and yet not in the MLN from FCoV-positive cats without
FIP. This fits with previously reported findings [12]. TLR2 is classically responsible for detecting
bacterial antigens but is suspected, from a human in vitro model, to have a role in detecting SARS-CoV
spike proteins [55,56]. TLR4 detects the lipopolysaccharides of Gram-negative bacteria. However
it appears to have a role in viral detection as mice deficient in this receptor were found to have
increased susceptibility to murine hepatitis virus, a betacoronavirus [57–59]. Both TLR2 and 4 may
also potentially react to alarmins, endogenous ligands released from damaged cells [60]. TLR8, as a
ssRNA sensor [61], is the only TLR of these three which would have been predicted to be elevated in
FCoV-infected cats. As none of these TLRs were elevated in the MLN of cats positive for FCoV in the
absence of FIP, this may reflect that a threshold level of the virus is required to activate their production
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(viral levels being at least a 1000-fold different between the FCoV-positive cats with and without FIP).
The range of antigen specificities across the three TLRs make it unlikely that non-pathogenic FCoV
would evade receptor triggering through intrinsic viral factors. The TLRs use Myd88 signaling, as well
as NF-κB [55]; the detected increases in these pathways are therefore likely to be linked. An alternative
explanation for the upregulation of bacterial response pathways is that as the MLN is exposed to any
intestinal pathogen, there is an increased likelihood of concurrent bacterial infection(s) stimulating
PRR/TLR responses and contributing to a permissive inflammatory environment. Co-infection would
certainly be an avenue for future exploration. The upregulation of collagen synthesis in the MLN
of cats with FIP likely reflects the progressive fibrosis in association with multiple granulomatous
infiltrates that is noted within the MLN in chronic cases of FIP (unpublished data).
There were few processes found to be significantly downregulated in the MLN of cats with FIP,
but those that were have major immunological implications. These included T cell receptor signaling
pathway, and IL-4 production. When genes from the categories T cell differentiation and T cell mediated
immunity were analysed separately, T cell features were relatively lower in FIP cats than either group of
cats without FIP. Consistent with this, anti-viral T cell responses (as determined by proliferation assays
and T cell subsets) were found to be higher in cats resistant to experimental FIP in a recent study [62].
This supports a deficiency in cats that succumb to the disease, either at the level of initial detection
(cell surface receptor signaling) or in sustaining an appropriate response. In the case of the latter, the
FCoV-positive cats without FIP may represent a precursor stage at which the host immune system is
able to contain the virus. One gene of significance here was FOXP3, upregulated in both groups of cats
without FIP. FOXP3 is a transcription factor with a central role in the function of CD4+ regulatory T
(Treg) cells [63]. Treg cells are crucial for maintaining immune homeostasis and can also suppress other
leukocytes, a function which would be expected to be beneficial in cats with an exuberant immune
response [63]. A reduction in Treg cells, and hence their immune regulatory effects, has also been
shown in the peripheral blood of cats with FIP [64]. IL-4 is a classical Th2 cytokine, responsible for
pushing Th2 differentiation and suppressing Th1. Whilst its decreased levels in the MLN of cats with
FIP may appear slightly counter intuitive, given that FIP is associated with a balance skewed to Th2,
this agrees with previous studies on cytokine levels and may represent end-stage disease [33,41]. It has
also been found to be lower in Holy Birman cats, a breed predisposed to FIP in Italy, than in a mixed
population of other breeds [65].
Results in FCoV-positive cats without FIP show that many of the same processes as in cats with
FIP are significantly upregulated, as compared to FCoV-negative cats without FIP, including viral
defense, leukocyte chemotaxis, IL-1 response, and IFN-response pathways. However, a closer look at
the individual gene levels of these processes shows that they are higher in cats with FIP than in both
groups of cats without FIP. This suggests that quantitative differences may be key. Indeed, in both
FCoV-positive groups (i.e., cats with and without FIP) there was upregulation of anti-viral IFN-related
genes but the inflammatory triad of IL-1, IL-6, and TNF, as well as CXCL10, a highly inflammatory
chemokine, were only elevated in the MLN of cats with FIP. Therefore, these are not likely to have any
positive contribution to viral defense and rather act to induce the observed pathological processes and
clinical signs. Despite the upregulation of type I IFN pathways, IFN-α and-β themselves were not
significantly upregulated in the MLN of cats with FIP, suggesting that further investigation into defects
in this pathway may be required. Transcription factors for IFN pathways (including IFN-regulatory
factors (IRF7 and 9), as well as IFN-stimulated genes (e.g., ISG15 and 20) and IFN-induced proteins
(IFIT2 and 3) were all elevated in both FCoV-positive groups. Members of the large (>70 member)
tripartite motif-containing (TRIM) family, some of which are involved in innate antiviral immunity [66],
were upregulated in both FCoV-positive groups and are also of interest. These proteins are involved in
ubiquitination, one of the effects of which is intracellular immune signal regulation. They are expressed
in response to IFN and can be predicted to have both positive and negative effects on the immune
response. TRIM targeting is also a virus evasion strategy and has been shown as a mechanism of
SARS-CoV [67,68]. Some have intrinsic anti-viral properties, e.g., TRIM25 [66], which was upregulated
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in both FCoV-positive groups. However, TRIM25 can also trigger inflammatory cytokine as well as
IFN production [66]. On the other hand, TRIM21, a protein that can degrade IRFs and thus reduce the
IFN response [69], was only elevated in the MLN of cats with FIP. TRIM21 can also detect intracellular,
antibody-opsonized virus which it targets for ubiquitination and degradation [69]. Subsequently,
the viral nucleic acid is released to be detected by PRRs in the cytoplasm. So far this has only been
identified as a relevant mechanism for non-enveloped viruses, however the effect of TRIM21 levels on
IFN would be an interesting topic for in vitro experiments of the FCoV infection.
Crucially, there is less upregulation of humoral immunity (e.g., immunoglobulin production, B
cell activation) in FCoV-positive cats without FIP in contrast to cats with FIP, further supporting the
early theories that this branch of the immune system is detrimental [6,45]. In cats with FIP surviving to
chronic stages of the disease, plasma cells replace macrophages in the granulomas and form layers in
serositis; a morphological evidence of excessive humoral activation [28].
Previous studies have found apoptosis to be a prominent feature in FIP, both morphologically
in the lymphoid tissue and at the signaling pathway level in macrophages [39,41,42]. In the current
study, intrinsic apoptotic pathways were found to be enriched in the MLN from cats with FIP (though
not found within the top ten categories). This may be because in end-stage FIP the active phase of
lymphoid depletion had already passed.
4. Materials and Methods
4.1. Case Selection
The study population consists of animals presented to either the university small animal hospitals
or local practices in Zurich, Switzerland, and Bristol, UK. All animals, with or without FIP, were
euthanized for purely clinical reasons. Cases are a subset of those previously published with the
exception of sample 2.9. University of Bristol FIP Biobank samples were collected at post-mortem
examination with full informed consent from owners that samples could be used for research purposes.
The collection, storage and use of samples used in this project were approved under ethical review by
the University of Bristol Animal Welfare and Ethical Review Board (VIN/14/013; VIN/18/003) [12–14].
Case signalment is presented in Supplementary Table S1. Group 1 (G1) consists of 14 cases in which
the diagnosis of FIP had been excluded (non-FIP cats). Following FCoV RT-qPCR on the MLN, G1
was subdivided into six G1_Pos cats (non-FIP with FCoV-positive MLN) and eight G1_Neg cats
(non-FIP with FCoV-negative MLN). Group 2 (G2) consisted of ten cats with FIP. The diagnosis
was based on clinical findings, macroscopical and histological alterations, together with the positive
immunohistological detection of the FCoV antigen (mouse monoclonal primary antibody [clone
FIPV3-70 Santa Cruz, Heidelberg, Germany]) within macrophages in typical lesions [70].
4.2. RNA Extraction from the MLN, cDNA Synthesis, and RT-qPCR for the Detection of FCoV
For RNA extraction, the RNeasy Plus Minikit® (Qiagen) with on column genomic DNA (gDNA)
removal was used following the manufacturer’s instructions. Briefly, approximately 30 mg of tissue
was thawed on ice and RNA extraction buffer was added. Following disruption and homogenization
using a tissue homogenizer (Mixer-Mill 300, Retsch, Haan, Germany), RNA was extracted and eluted.
Remaining gDNA was removed by an additional DNase step (ezDNase; Thermo Fisher Scientific;
Waltham, MA, USA). Complementary (cDNA) synthesis was performed with the High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Before
conducting RT-qPCR, the RNA levels of the samples were adjusted to 400 ng/µL, by measuring the
concentration with a NanoDrop 2000® (Thermo Fisher Scientific) and further diluted 1 in 20. TaqMan
RT-qPCR was performed as previously described using a Biosystems 7500 Fast PCR System® (Thermo
Fisher Scientific) and published protocols [71].
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4.3. RNA Extraction and Library Preparation for Next Generation RNA-Sequencing
A Qubit® (1.0) Fluorometer (Life Technologies, Carlsbad, CA, USA) and a Bioanalyzer 2100
were used to determine the RNA quality; only samples with a 260/280 nm ratio between 1.8–2.1 and
a 28S/18S ratio within 1.5–2 were processed. Following the manufacturer’s protocol, the stranded
(antisense) TruSeq RNA Sample Prep Kit v2 (Illumina, Inc. San Diego, CA, USA) was used. After
polyA enrichment of total RNA, the samples were reverse-transcribed into cDNA. This was followed
by fragmentation, end-repair, and polyadenylation, before ligation of the TruSeq adapters (containing
an index). This allows multiplexing fragments and selective enrichment by PCR. For validating the
quality and quantity of the libraries, the Qubit® (1.0) Fluorometer and the Caliper GX LabChip® GX
(Caliper Life Sciences, Inc., Waltham, MA, USA) were used. The product is a smear with an average
fragment size of approximately 260 bp. The libraries were normalized to 10 nM in Tris-Cl 10 mM, pH
8.5 with 0.1% Tween 20.
4.4. Sequencing on NovaSeq 6000
After library quantification, libraries were prepared for loading according to the NovaSeq XP
workflow with the NovaSeq6000 SP Reagent Kit (Illumina, Catalog No. 20027464, San Diego, CA, USA).
Cluster generation and sequencing were performed on a NovaSeq6000 System with a run configuration
of single end 100 bp.
4.5. Statistical Analysis
Reads were quality-checked with FastQC (Babraham bioinformatics, Cambridge, UK). Sequencing
adapters were removed with Trimmomatic [72] and aligned to the reference genome and transcriptome
of Felis catus (Ensemble, v 6.2) with STAR v 2.7.3 [73] using the following options: –outFilterType
BySJout –outFilterMatchNmin 30 –outFilterMismatchNmax 10 –outFilterMismatchNoverLmax
0.05 –outMultimapperOrder Random –alignSJDBoverhangMin 1 –alignSJoverhangMin 8
–alignIntronMax 100,000 –alignMatesGapMax 100,000 –outFilterMultimapNmax 50 –chimSegmentMin
15 –chimJunctionOverhangMin 15 –chimScoreMin 15 –chimScoreSeparation 10 –outSAMstrandField
intronMotif –alignEndsProtrude 3 ConcordantPair.
Distribution of the reads across genomic isoform expression was quantified using the R package
GenomicRanges [74]. Minimum mapping quality, as well as minimum feature overlaps, was set to 10.
Multi-overlaps were allowed and strand-specificity was set to 2 (antisense).
Differentially expressed (DE) genes were identified using the R package edgeR [75], using a
generalized linear model (glm) regression, a quasi-likelihood (QL) differential expression test, and
the trimmed means of M-values (TMM) normalization. In the pair-wise comparisons, genes with at
least ten raw counts in at least 50% of the samples in at least one of the two groups were reported as
present and a test was performed. Of those, genes with a p < 0.01 and a log2 fold-ratio > 0.5 (<−0.5)
were marked as differentially upregulated (respectively downregulated).
Enrichment of GO terms was performed using the hypergeometric test as implemented in the R
function enricher, from the package clusterProfiler [76].
The multi-dimensional scaling plot was generated with the R function plotMDS from the package
limma [77] and the heat map with the R package pheatmap [78].
The potential effect of additional covariates has been tested using PERMANOVA (with 999
permutations) as implemented in the R function adonis2 from the package Vegan [79].
All R packages used were from Bioconductor Version 3.10.
For all pairwise comparisons, the enrichment plots show the top 10 most enriched biological
processes (GO BP) based on significantly up or downregulated genes. Tables with the full lists of
significantly enriched GO terms are provided in the Supplementary Materials.
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5. Conclusions
In conclusion, our findings highlight the difference in host response to FCoV in the context of
systemic infection both in cats with and without FIP. They demonstrate the extent of immune system
activation in FIP as well as the skew towards a pro-inflammatory cytokine response and further
demonstrate the importance of a strong T cell-mediated immunity in mounting an effective response to
FCoV infection. Comparisons of host response to infection with different clinical outcomes (i.e., FIP vs.
no FIP) also support the initial hypothesis that an excessive pro-inflammatory response is responsible
for FIP.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/9/7/524/s1,
Figure S1: Summary of the reads mapping and gene quantification. (A) Box-plots of the distribution across the
samples of the fraction (in%) of reads mapped to the genome and to coding regions (relative to the number of raw
reads) and of the genes identified beyond background noise (relative to the number of genes in the annotation).
(B) Number of differentially expressed genes in the pair-wise comparisons; Figure S2: Percentage of sequencing
reads mapping to the rRNA silva database and showing strandedness information; Figure S3: Multidimensional
scaling plot showing the main segregation of G2 from both G1 subgroups along the leading dimension. In
these plots, the covariates of interest are also annotated and reveal no particular structure. The negligible effects
from the covariates have also been tested using a PERMANOVA test. (A) Age: The samples are grouped by
age intervals. P-PERMANOVA = 0.536. (B) Breed: The samples are grouped by breed. P-PERMANOVA =
0.734. (C) Breed: The samples are grouped by sex. P-PERMANOVA = 0.173; Table S1: Signalment and relevant
pathological findings of all cases; Table S2: GO categories significantly enriched (Benjamini-Hochberg fdr < 0.05)
for significantly upregulated and downregulated (italics) genes in the MLN of FIP cats compared to non-FIP cats;
Table S3: GO categories significantly enriched (Benjamini-Hochberg fdr < 0.05) for significantly upregulated and
downregulated (italics) genes in the MLN of FIP cats compared to FCoV-negative non-FIP cats; Table S4: GO
categories significantly enriched (Benjamini-Hochberg fdr < 0.05) for significantly upregulated and downregulated
(italics) genes in the MLN of FIP cats compared to FCoV-positive non-FIP cats; Table S5: GO categories significantly
enriched (Benjamini-Hochberg fdr < 0.05) for significantly upregulated and downregulated (italics) genes in the
MLN of FCoV-positive non-FIP cats compared to FCoV-negative non-FIP cats; Table S6: The top 30 significant
differentially expressed genes in the MLN of FIP vs. non-FIP cats.
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